[The value of serum CA 125 for monitoring treatment of patients with ovarian cancer].
To evaluate the value of serum CA 125 antigen in monitoring of treatment of ovarian carcinoma, serum levels of this marker were monthly assayed during treatment and follow-up period in a group of 112 patients. CA 125 levels decreased in all 67 patients with remission. In a group of 41 patients with progressive disease, in 38 (93%) CA 125 levels increased, and in 3 (7%) - remained elevated. CA 125 became negative in all patients with clinical complete remission, although in 14 (38%) patients in this group second-look laparotomy revealed microscopic disease. In 12 of 15 patients with complete pathologic remission the increase of CA 125 preceded (2 to 58 weeks, median - 12 weeks) the recurrence of the disease. Time to progression depended on the increase rate of the antigen level.